Suppliers for CAS
857876-30-3
|
Properties | CAS |
857876-30-3 | Formula |
C22H23N5O.2H3O4P |
|
7 Registered suppliers
Amadis Chemical Company Limited
P.R.China
More details are to be found here
Dayang Chem (Hangzhou) Co.,Ltd.
P.R.China
More details are to be found here
Leap Chem Co., Ltd
P.R.China
Molecular Formula: C22H29N5O9P2 Molecular Weight: 569.441282
Aea.ltd
P.R.China
Molecular Formula: C22H29N5O9P2 Molecular Weight: 569.441282
BOC Sciences
USA
Description : Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. - Molecular Weight :569.44
- Purity :> 98%
Molecular Formula : C22H29N5O9P2 Canonical SMILES : CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O InChI : InChI=1S/C22H23N5O.2H3O4P/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15;2*1-5(2,3)4/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28);2*(H3,1,2,3,4) InChIKey : ONDPWWDPQDCQNJ-UHFFFAOYSA-N Application : Protein Kinase Inhibitors Synonyms : Motesanib diphosphate; 857876-30-3; AMG-706; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); Motesanib diphosphate [USAN]; Motesanib phosphate; AMG 706 (Diphosphate); AMG 706; ; T6Q3060U91; Motesanib phosphate (JAN); Motesanib diphosphate (USAN); N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; phosphoric acid; MOTESANIB PHOSPHATE [JAN]; 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2)
More details are to be found here
Chemos GmbH & Co. KG
Germany
Description : Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. - Molecular Weight :569.44
- Purity :> 98%
Molecular Formula : C22H29N5O9P2 Canonical SMILES : CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O InChI : InChI=1S/C22H23N5O.2H3O4P/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15;2*1-5(2,3)4/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28);2*(H3,1,2,3,4) InChIKey : ONDPWWDPQDCQNJ-UHFFFAOYSA-N Application : Protein Kinase Inhibitors Synonyms : Motesanib diphosphate; 857876-30-3; AMG-706; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); Motesanib diphosphate [USAN]; Motesanib phosphate; AMG 706 (Diphosphate); AMG 706; ; T6Q3060U91; Motesanib phosphate (JAN); Motesanib diphosphate (USAN); N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; phosphoric acid; MOTESANIB PHOSPHATE [JAN]; 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2)
More details are to be found here
Santa Cruz Biotechnology, Inc.
USA
Description : Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. - Molecular Weight :569.44
- Purity :> 98%
Molecular Formula : C22H29N5O9P2 Canonical SMILES : CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O InChI : InChI=1S/C22H23N5O.2H3O4P/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15;2*1-5(2,3)4/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28);2*(H3,1,2,3,4) InChIKey : ONDPWWDPQDCQNJ-UHFFFAOYSA-N Application : Protein Kinase Inhibitors Synonyms : Motesanib diphosphate; 857876-30-3; AMG-706; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); Motesanib diphosphate [USAN]; Motesanib phosphate; AMG 706 (Diphosphate); AMG 706; ; T6Q3060U91; Motesanib phosphate (JAN); Motesanib diphosphate (USAN); N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; phosphoric acid; MOTESANIB PHOSPHATE [JAN]; 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2)
More details are to be found here
|